Literature DB >> 15070994

Epidemiology and clinical course of Burkholderia cepacia complex infections, particularly those caused by different Burkholderia cenocepacia strains, among patients attending an Italian Cystic Fibrosis Center.

Graziana Manno1, Claudia Dalmastri, Silvia Tabacchioni, Peter Vandamme, Renata Lorini, Laura Minicucci, Luca Romano, Alessandro Giannattasio, Luigi Chiarini, Annamaria Bevivino.   

Abstract

In this study, the epidemiology of Burkholderia cepacia complex (Bcc) recovered from the sputum of 75 patients attending the Genoa Cystic Fibrosis (CF) Center at the Gaslini Children's Hospital (Genoa, Italy) was investigated, and the clinical course of the CF patients infected with the different species and genomovars of Bcc was evaluated. All isolates were analyzed for genomovar status by recA gene polymorphism and subsequently random amplified polymorphic DNA fingerprinting. Burkholderia cenocepacia is the predominant species recovered from the CF patients infected with Bcc at the Genoa CF Center. Of the other eight species comprising the Bcc, only a few isolates belonging to B. cepacia genomovar I, Burkholderia stabilis, and Burkholderia pyrrocinia were found. Of the four recA lineages of B. cenocepacia, most patients were infected by epidemic strains belonging to lineages IIIA and IIID, whereas only a few patients harbored IIIB strains. Patient-to-patient spread of Bcc among CF patients was mostly associated with B. cenocepacia, in particular with strains belonging to recA lineages IIIA and IIID. The mortality of CF patients infected with Bcc at the Genoa CF Center was significantly higher than mortality among CF patients not infected with Bcc. All of the deaths were associated with the presence of B. cenocepacia, except the case of a patient infected with B. cepacia genomovar I. Within B. cenocepacia, infection with epidemic strains belonging to lineages IIIA and IIID was associated with higher rates of mortality than was infection with lineage IIIB strains. No significant differences in lung function, body weight, and mortality rate were observed between patients infected with epidemic strains belonging to either B. cenocepacia IIIA or B. cenocepacia IIID.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15070994      PMCID: PMC387599          DOI: 10.1128/JCM.42.4.1491-1497.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  18 in total

1.  Phenotypic methods for determining genomovar status of the Burkholderia cepacia complex.

Authors:  D A Henry; E Mahenthiralingam; P Vandamme; T Coenye; D P Speert
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

Review 2.  Taxonomy and identification of the Burkholderia cepacia complex.

Authors:  T Coenye; P Vandamme; J R Govan; J J LiPuma
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

3.  Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis.

Authors:  J J LiPuma; T Spilker; L H Gill; P W Campbell; L Liu; E Mahenthiralingam
Journal:  Am J Respir Crit Care Med       Date:  2001-07-01       Impact factor: 21.405

4.  Burkholderia cepacia complex: distribution of genomovars among isolates from the maize rhizosphere in Italy.

Authors:  A Fiore; S Laevens; A Bevivino; C Dalmastri; S Tabacchioni; P Vandamme; L Chiarini
Journal:  Environ Microbiol       Date:  2001-02       Impact factor: 5.491

5.  Burkholderia cepacia complex infection in Italian patients with cystic fibrosis: prevalence, epidemiology, and genomovar status.

Authors:  A Agodi; E Mahenthiralingam; M Barchitta; V Gianninò; A Sciacca; S Stefani
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

6.  Burkholderia cepacia in cystic fibrosis. Variable disease course.

Authors:  D D Frangolias; E Mahenthiralingam; S Rae; J M Raboud; A G Davidson; R Wittmann; P G Wilcox
Journal:  Am J Respir Crit Care Med       Date:  1999-11       Impact factor: 21.405

7.  Distribution of genes encoding putative transmissibility factors among epidemic and nonepidemic strains of Burkholderia cepacia from cystic fibrosis patients in the United Kingdom.

Authors:  F E Clode; M E Kaufmann; H Malnick; T L Pitt
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

8.  DNA-Based diagnostic approaches for identification of Burkholderia cepacia complex, Burkholderia vietnamiensis, Burkholderia multivorans, Burkholderia stabilis, and Burkholderia cepacia genomovars I and III.

Authors:  E Mahenthiralingam; J Bischof; S K Byrne; C Radomski; J E Davies; Y Av-Gay; P Vandamme
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

9.  Identification and population structure of Burkholderia stabilis sp. nov. (formerly Burkholderia cepacia genomovar IV).

Authors:  P Vandamme; E Mahenthiralingam; B Holmes; T Coenye; B Hoste; P De Vos; D Henry; D P Speert
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

10.  Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans.

Authors:  E Mahenthiralingam; P Vandamme; M E Campbell; D A Henry; A M Gravelle; L T Wong; A G Davidson; P G Wilcox; B Nakielna; D P Speert
Journal:  Clin Infect Dis       Date:  2001-10-04       Impact factor: 9.079

View more
  24 in total

Review 1.  A decade of Burkholderia cenocepacia virulence determinant research.

Authors:  Slade A Loutet; Miguel A Valvano
Journal:  Infect Immun       Date:  2010-07-19       Impact factor: 3.441

2.  Metabolic profiling of Burkholderia cenocepacia, Burkholderia ambifaria, and Burkholderia pyrrocinia isolates from maize rhizosphere.

Authors:  Chiara Alisi; Giovanna Jona Lasinio; Claudia Dalmastri; AnnaRosa Sprocati; Silvia Tabacchioni; Annamaria Bevivino; Luigi Chiarini
Journal:  Microb Ecol       Date:  2005-11-25       Impact factor: 4.552

3.  Revised approach for identification of isolates within the Burkholderia cepacia complex and description of clinical isolates not assigned to any of the known genomovars.

Authors:  Jane F Turton; Nazia Arif; Daneeta Hennessy; Mary E Kaufmann; Tyrone L Pitt
Journal:  J Clin Microbiol       Date:  2007-07-11       Impact factor: 5.948

4.  Pseudomonas and Aeromonas isolates from domestic reptiles and study of their antimicrobial in vitro sensitivity.

Authors:  V V Ebani; F Fratini; M Ampola; E Rizzo; D Cerri; E Andreani
Journal:  Vet Res Commun       Date:  2008-09       Impact factor: 2.459

5.  Transmission of Burkholderia cepacia complex: evidence for new epidemic clones infecting cystic fibrosis patients in Italy.

Authors:  S Campana; G Taccetti; N Ravenni; F Favari; L Cariani; A Sciacca; D Savoia; A Collura; E Fiscarelli; G De Intinis; M Busetti; A Cipolloni; A d'Aprile; E Provenzano; I Collebrusco; P Frontini; G Stassi; M Trancassini; D Tovagliari; A Lavitola; C J Doherty; T Coenye; J R W Govan; P Vandamme
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

Review 6.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 7.  Lung transplantation for cystic fibrosis: results, indications, complications, and controversies.

Authors:  Joseph P Lynch; David M Sayah; John A Belperio; S Sam Weigt
Journal:  Semin Respir Crit Care Med       Date:  2015-03-31       Impact factor: 3.119

8.  Burkholderia cepacia complex in cystic fibrosis in the post-epidemic period: multilocus sequence typing-based approach.

Authors:  Libor Fila; Pavel Dřevínek
Journal:  Folia Microbiol (Praha)       Date:  2017-03-31       Impact factor: 2.099

Review 9.  Indications for lung transplant referral and listing.

Authors:  Omar Shweish; Goutham Dronavalli
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

Review 10.  Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiological assessment.

Authors:  Samuel M Moskowitz; Ronald L Gibson; Eric L Effmann
Journal:  Pediatr Radiol       Date:  2005-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.